Find Locations
For hours, walk-ins and appointments.Synonyms
- EBV in situ Hybridization
Test Includes
DNA probe hybridization for EBV in formalin-fixed, paraffin-embedded tissue
Special Instructions
Please direct any questions regarding this test to oncology customer service at 800-345-4363.
Expected Turnaround Time
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Formalin-fixed, paraffin-embedded (FFPE) tissue biopsy. Tissue biopsies should be fixed in 10% neutral-buffered formalin and embedded in paraffin within 72 hours. Do not submit frozen tissue or substitute other fixatives. For tissues submitted in formalin, please provide the appropriate gross/microscopic description indicating the number, type, and sites of the tissue submitted.
Container
Submit paraffin block in crushproof container. Submit fresh tissue in a sterile container in 10% neutral-buffered formalin.
Collection
Tissue biopsies should be fixed in 10% neutral buffered formalin and embedded in paraffin within 72 hours. Do not submit frozen tissue or substitute other fixatives. For tissues submitted in formalin, please provide appropriate gross/microscopic description indicating the number, type, and site of the tissue(s) submitted.
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Insufficient tissue; improper fixation; inappropriate fixative
Test Details
Use
Detect EBV DNA sequences in tissue sections; adjunct to histopathology
Limitations
Failure to detect target DNA may result from several factors, eg, improper sampling, handling, and/or fixative of the specimen, or target DNA below the sensitivity limits of the assay; therefore, lack of staining does not necessarily imply the absence of target DNA.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.
Methodology
In situ hybridization
References
Berg LC, Copenhaver CM, Morrison VA, et al. B-cell lymphoproliferative disorders in solid-organ transplant patients: Detection of Epstein-Barr virus by in situ hybridization. Hum Pathol. 1992 Feb; 23(2):159-163. 1310951
De Souza YG, Freese UK, Greenspan D, Greenspan JS. Diagnosis of Epstein-Barr virus infection in hairy leukoplakia by using nucleic acid hybridization and noninvasive techniques. J Clin Microbiol. 1990 Dec; 28(12):2775-2778. 2177752
Hamilton-Dutoit SJ, Delecluse HJ, Raphael M, Lenoir G, Pallesen G. Detection of Epstein-Barr virus genomes in AIDS related lymphomas: sensitivity and specificity of in situ hybridisation compared with Southern blotting. J Clin Pathol. 1991 Aug; 44(8):676-680. 1653789
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 550913 | Epstein-Barr Virus, DNA Probe | 5004-7 | 550919 | EBV, DNA Probe | 5004-7 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf